Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | PRCP | P42785 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gacyclidine SCHEMBL7190367 | 1.00 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL397836 | 1.00 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL3457748 | 1.00 | SIGMAR1 (0.57) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL5398234 | 0.99 | SIGMAR1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL1662223 | 0.99 | SIGMAR1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| SCHEMBL8206550 | 0.83 | MEN1 (0.42) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Hydrochloric Acid SCHEMBL8205944 | 0.82 | MEN1 (0.41) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| SCHEMBL7700857 | 0.81 | PRCP (0.51) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL5402379 | 0.79 | CYP1A2 (0.45) | SIGMAR1PRCPMEN1KMT2ASLC6A3 | |
| Gacyclidine SCHEMBL14053284 | 0.78 | GRIN1 (0.56) | SIGMAR1PRCPMEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023780-A1 | Therapeutic use of a derivative of thienylcyclohexylamine | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-01-22 | — | — | US | claimed |
| EP-1359914-B1 | NOVEL THERAPEUTIC USE OF A THIENYLCYCLOHEXYLAMINE DERIVATIVE FOR TREATING PAIN | SOD CONSEILS RECH APPLIC (FR) | 2006-08-30 | — | — | EP | claimed |
| US-20050032840-A1 | Novel therapeutic use of a thienylcyclohexylamine derivative | NEUREVA (FR) | 2005-02-10 | — | — | US | claimed |
| US-5972952-A | THERAPY FOR STROKE, NERVOUS SYSTEM DISORDERS, ALZHEIMER'SDISEASE | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1999-10-26 | — | — | US | claimed |
| WO-2010142890-A1 | COMPOSITION INCLUDING A MOLECULE PROMOTING THE NEURON-GLIA INTERACTION, IN PARTICULAR FOR PREVENTING THE FORMATION OF THE GLIAL SCAR AND INDUCING NEURAL REGENERATION | NEUREVA (FR) | 2010-12-16 | — | — | WO | disclosed |
| US-20100173874-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-20100173874-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION | 2010-07-08 | — | — | US | disclosed |
| US-7589110-B2 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589110-B2 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090023780-A1 | Therapeutic use of a derivative of thienylcyclohexylamine | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-01-22 | — | — | US | disclosed |
| US-20070015727-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION AND INSERM | 2007-01-18 | — | — | US | disclosed |
| US-20070015727-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | DURECT CORPORATION AND INSERM | 2007-01-18 | — | — | US | disclosed |
| EP-1359914-B1 | NOVEL THERAPEUTIC USE OF A THIENYLCYCLOHEXYLAMINE DERIVATIVE FOR TREATING PAIN | SOD CONSEILS RECH APPLIC (FR) | 2006-08-30 | — | — | EP | disclosed |
| US-20050032840-A1 | Novel therapeutic use of a thienylcyclohexylamine derivative | NEUREVA (FR) | 2005-02-10 | — | — | US | disclosed |
| US-6524629-B1 | 20-30% of flavoneglycosides, 2.5-4.5% of ginkgolides A, B, C, and J, 2-4% of biloblaide, < 10% proanthocyanidines, < 10 ppm of an alkylphenol and ginkobiloba extract | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-02-25 | — | — | US | disclosed |
| US-5972952-A | THERAPY FOR STROKE, NERVOUS SYSTEM DISORDERS, ALZHEIMER'SDISEASE | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173874-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | SLC1A2, GRM6, GRIK4 | SIGMAR1 2458/4885PRCP 2061/4885MEN1 1151/4885 |
| US-20070015727-A1 | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear | SLC1A2, GRM6, GRIK4 | SIGMAR1 2458/4885PRCP 2061/4885MEN1 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.